EC16 Nanoparticles for preventing Alzheimer’s risk linked to gum disease
Official title: EC16 Nanoparticles: Bridging Oral Health and Alzheimer's Prevention via FAST Nanotechnology
Funded at Camellix, LLC · NIH-11404985 · Data updated 2026-11-12
A tiny, edible nanoparticle treatment from Camellix aims to reduce gum infection and may help lower the risk of developing Alzheimer's disease in older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Camellix, LLC NIH-funded |
| Lab location | 1 site (Evans, United States) |
| Project start | September 24, 2026 |
| Project end | September 23, 2027 |
| Funding year | 2026 |
| Award (this year) | $499,999 |
| NIH project number | 1R41AG102092-01 |
| Project ID | NIH-11404985 on NIH RePORTER |
Who could benefit from this research
✓Could help
Older adults at risk for periodontal disease and/or Alzheimer’s disease, especially those with a history of gum disease or systemic inflammation.
✕Less likely to help
Individuals without periodontal disease or Alzheimer's risk may receive limited direct benefit from this preventive approach.
What this research studies
This project tests a safe, food-grade nanoparticle formulation called EC16, designed to fight periodontal infection and inflammation. Researchers will study how EC16 works against multiple oral bacteria and biofilms, and whether it can prevent gum disease from progressing. By reducing oral inflammation, the team hopes to lower signals of brain inflammation associated with Alzheimer's risk in aging adults. The study leverages a translational approach, moving from animal models to potential human use, with patient safety and compliance in mind.
Why it matters
Potential benefit: If successful, the EC16 oral formulation could become a preventive option to reduce periodontal disease and potentially lower the risk or progression of Alzheimer’s-related changes in the brain.
How similar studies have gone: Preclinical studies in animal models have shown antimicrobial and anti-inflammatory effects of EC16; human data are not yet established.
Where this research is happening
-
Camellix, LLC
Evans, United States Active
Researchers
- Principal investigator: Hsu, Stephen — Camellix, LLC
- Study coordinator: Hsu, Stephen
Related research
Other NIH-funded projects on the same topics.
-
Coordinated Oral Health Promotion for Chicago Kids
A long-running study in Chicago is following children and their caregivers to find ways to reduce tooth decay and improve daily life for families.
-
Digital adolescent dental health program to reduce tooth decay in at-risk youth
A digital program designed for lower-income 7th and 8th graders to help them avoid tobacco use and sugary drinks to lower the risk of tooth decay.
-
Improving how schools deliver tooth care for kids using existing data
This project analyzes past school-based dental care data to help more underserved children get effective, affordable preventive treatment.
-
Host genetics and oral microbiome: big-data clues to oral health
A large study will combine human genetics, saliva bacteria, and health records to understand why oral diseases like cavities and gum disease occur in different people.
-
Understanding dry mouth in adults using AI to read electronic records
A new project uses AI to find adults with xerostomia in medical records and predict who will have worse oral health outcomes.
-
Oral health effects of buprenorphine and methadone in people with opioid use disorder
This project will explore how common MOUD medicines like buprenorphine (including dissolvable forms) and methadone may affect oral health in people with opioid use disorder.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.